[
  {
    "ts": "2025-11-11T13:00:00+00:00",
    "headline": "Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine",
    "summary": "Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar TherapeuticsLOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced it has been named as one of the “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine. “",
    "url": "https://finance.yahoo.com/news/turn-therapeutics-gx-03-technology-130000938.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "e278ef48-d162-3e77-a348-283cb9b57777",
      "content": {
        "id": "e278ef48-d162-3e77-a348-283cb9b57777",
        "contentType": "STORY",
        "title": "Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine",
        "description": "",
        "summary": "Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar TherapeuticsLOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced it has been named as one of the “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine. “",
        "pubDate": "2025-11-11T13:00:00Z",
        "displayTime": "2025-11-11T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/5174144e426c29f941b226cbf53dd813",
          "originalWidth": 376,
          "originalHeight": 126,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SFyDI6.pP.2tNxaLV86zog--~B/aD0xMjY7dz0zNzY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5174144e426c29f941b226cbf53dd813.cf.webp",
              "width": 376,
              "height": 126,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2qq5dhaRIOLOknWzA4KLmg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5174144e426c29f941b226cbf53dd813.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/turn-therapeutics-gx-03-technology-130000938.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/turn-therapeutics-gx-03-technology-130000938.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TTRX"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "APGE"
            },
            {
              "symbol": "NKTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T10:30:00+00:00",
    "headline": "Obesity Drugs Are About to Go Mass-Market",
    "summary": "For most of Big Pharma, drug discounts have largely been about damage control.  After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief.  For  Eli Lilly’s    David Ricks  and  Novo Nordisk’s    Mike Doustdar,  who paid their own visit to the White House last week, the calculus is different.",
    "url": "https://www.wsj.com/health/pharma/ozempic-glp1-weight-loss-mass-market-f70f8484?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "b2aa9d81-f8af-30ce-a574-a07b350656b9",
      "content": {
        "id": "b2aa9d81-f8af-30ce-a574-a07b350656b9",
        "contentType": "STORY",
        "title": "Obesity Drugs Are About to Go Mass-Market",
        "description": "",
        "summary": "For most of Big Pharma, drug discounts have largely been about damage control.  After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief.  For  Eli Lilly’s    David Ricks  and  Novo Nordisk’s    Mike Doustdar,  who paid their own visit to the White House last week, the calculus is different.",
        "pubDate": "2025-11-11T10:30:00Z",
        "displayTime": "2025-11-11T10:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/b2aa9d81-f8af-30ce-a574-a07b350656b9/obesity-drugs-are-about-to-go.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/d9fbb83aa02eec1c9b51828685ea6e31",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r3EYtfWi7DUenDdrNOIVjQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/d9fbb83aa02eec1c9b51828685ea6e31.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/T5qoowdQPCQB7Wmdu4lvWA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/d9fbb83aa02eec1c9b51828685ea6e31.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/ozempic-glp1-weight-loss-mass-market-f70f8484?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]